“The new platform will improve data management to support accelerated research and development of new therapies,” said John Potthoff, PhD, CEO of Elligo, a clinical research infrastructure (CRI) provider.
The company’s services suite provides tools and technologies to accelerate patient identification, enrollment, study initiation and conclusion.
The new platform will leverage Samma Technologies’ Life Science Analytics Cloud, which is powered by its AI-enabled Fluid Analytics Engine to support patient population identification based on clinical trial eligibility requirements, according to the company.
“Embedding Saama’s analytics engine within Elligo’s new technology platform also will allow us to bring new insights to the clinical research process,” added Potthoff, who said the companies decided to partner because both bring a different perspective to the clinical trial landscape.
“Our goal is to improve awareness of, access to, and participation in clinical trials for US physicians and patients,” he told Outsourcing-Pharma.com.
“We hope to disrupt the way source data is collected and analyzed, not only enabling improved quality and efficiencies at the research site, but helping sponsors achieve their objectives faster.”
Elligo is aiming to pilot the new platform in a study this year and to use it for all new studies moving forward in 2019.
“We are excited to embark on this important project for both companies,” added Potthoff. “Together we can help trial sponsors assemble vast amounts of data from disparate sources and continue to provide innovative solutions to enable more patients and sites to participate in clinical trials.”